COVID taught Africa an expensive lesson — the continent imports more than 95% of its medicines, and when global supply chains seized, it was last in line. That lesson has become both an industrial policy and a market. BioNTech’s 35,000-square-metre mRNA vaccine facility in Kigali — the first commercial mRNA plant in Africa — won up to €95 million in EU blended financing in October 2025, backed by a CEPI grant of up to €130 million, to produce vaccines for malaria, tuberculosis, HIV, and mpox (1)(2). Kenya signed a $500 million deal with China for local vaccine and pharmaceutical production, and the IFC is actively recruiting private investment into African pharma (3)(4). Pharma localization is the rare sector where health security, industrial policy, and investor returns all point the same direction.
Key Takeaways
- Africa imports more than 95% of its medicines — a dependency COVID exposed as a strategic vulnerability, now driving an industrial-policy and market response.
- BioNTech’s 35,000 m² mRNA facility in Kigali, the first commercial mRNA plant in Africa, won up to €95 million in EU blended financing (a €35M EC grant plus a potential €60M EIB loan), with a CEPI grant of up to €130 million, to make vaccines for malaria, TB, HIV, and mpox (1)(2).
- Kenya signed a $500 million deal with China in 2025 for local vaccine and pharmaceutical production, and the IFC is actively recruiting private investment into African pharma manufacturing (3)(4).
- The sober reality: only about five active pharmaceutical-ingredient (API) plants exist on the whole continent, so the realistic near-term play is fill-finish, generics, packaging, and the supplier ecosystem — not APIs (5).
- Africa’s pharmaceutical market exceeds $50 billion, and procurement rules (Africa CDC’s target of 60% local vaccine production by 2040) are deliberately tilting demand toward local plants (5).
- First movers in quality manufacturing and its supply chain get a protected runway, because demand is being policy-guaranteed toward local production — a rare alignment of market and mandate.
Why is pharma localization suddenly an industrial priority?
Because a vulnerability that was tolerable in normal times became intolerable in a crisis — and crises change policy permanently.
For decades, Africa’s near-total dependence on imported medicines — more than 95% of pharmaceuticals are imported — was treated as an acceptable feature of global trade. It was cheaper to buy from established manufacturers in India, China, and Europe than to build domestic capacity, so the continent did not. Then COVID arrived, and the cost of that dependency became suddenly, painfully visible: when global supply chains seized and rich countries hoarded vaccines and essential medicines, Africa was last in line, waiting for doses while its people died. The pandemic converted an abstract economic dependency into a concrete strategic and moral failure — and that conversion is what makes the current localization push durable rather than faddish. Health security is now understood, correctly, as a form of national security, and no government wants to repeat the experience of being unable to protect its own population because the medicine was made somewhere else.
This is why pharma localization has become an industrial policy, not just a business opportunity. Governments and continental bodies are actively tilting the playing field toward local production — through procurement preferences, financing support, and explicit targets. Africa CDC has set a target of 60% local vaccine production by 2040 (5), a deliberate, decades-long commitment to build the demand certainty that local manufacturers need. When demand is policy-guaranteed in this way, the investment case transforms: a manufacturer is no longer betting on winning an open market, but on serving a market being steered toward it by policy. That is the rare alignment that makes pharma localization compelling — health security, industrial policy, and investor returns all pointing the same way.
What does the BioNTech Kigali facility prove?
It proves that world-class pharmaceutical manufacturing can be anchored in East Africa with serious international capital and a real production mandate — and it serves as the region’s flagship proof point.
BioNTech — the company behind one of the world’s leading COVID vaccines — built a 35,000-square-metre mRNA manufacturing facility in Kigali, Rwanda, designed to be the first commercial mRNA vaccine plant in Africa (1)(2). The financing tells you how serious this is. The European Investment Bank and European Commission committed up to €95 million in blended financing — structured as a €35 million EC grant plus a potential €60 million EIB loan — and a CEPI grant of up to €130 million supports the broader project (1). The facility is designed to produce vaccines for the diseases that matter most to Africa: malaria, tuberculosis, HIV, and mpox (2). This is not a token gesture or a vanity project; it is a genuine, commercial-scale manufacturing investment, anchored by one of the world’s most advanced biotech companies and backed by hundreds of millions in development and innovation finance.
The strategic significance extends beyond the doses it will make. The Kigali facility is an anchor tenant for an industry. A commercial mRNA plant requires a supply chain — cold chain, packaging, lab services, quality control, skilled technicians, supporting suppliers — and that ecosystem, once built around the anchor, can serve other manufacturers and adjacent industries. Rwanda’s role here is characteristic: it is functioning as the region’s proof-of-concept state, proving that advanced regulated manufacturing can work in East Africa before the model scales across the continent. The BioNTech facility is the demonstration that East Africa can host the high end of pharmaceutical manufacturing. The question for entrepreneurs and investors is which parts of the value chain they can realistically build around such anchors — and the honest answer is more pragmatic than the headlines suggest.
What is the realistic near-term opportunity?
Fill-finish, generics, packaging, and the supplier ecosystem — not active pharmaceutical ingredients. Getting this distinction right is the difference between a viable business and an expensive mistake.
The headline-grabbing end of pharma manufacturing is the production of active pharmaceutical ingredients (APIs) — the complex chemical synthesis at the base of every medicine. It is tempting to aim there, but the economics are unforgiving: API production is extraordinarily capital-intensive, scale-dependent, and technically demanding, which is why only about five active API plants exist on the entire continent (5). Trying to leapfrog directly into API manufacturing, against established global producers operating at vast scale, is the kind of ambition that burns capital. The realistic near-term play sits further down the value chain, where the economics work and the policy tailwind is just as strong:
Fill-finish — taking imported or regionally produced active ingredients and formulating, filling, and finishing them into final dosage forms (vials, tablets, injectables). This is less capital-intensive than API synthesis, benefits directly from local-production procurement preferences, and is exactly the kind of manufacturing the BioNTech-style anchors and policy targets are designed to localize.
Generics — manufacturing off-patent medicines for the region’s high-volume disease burden. Generics serve enormous, certain demand and benefit from the same procurement tilt toward local production.
Packaging and supply ecosystem — the cold chain, packaging, lab services, quality assurance, and component supply that every pharmaceutical plant requires. These supplier businesses are lower-risk, cash-generating, and ride the entire sector’s growth without bearing the capital intensity of drug synthesis itself.
The strategic discipline is to climb the value chain rather than leap to its top. Build fill-finish, generics, packaging, and supply capability first — viable today, policy-supported, serving certain demand — and let API capacity come later, if and when scale justifies it. The protected runway that policy creates rewards the first movers who build quality capability at the achievable rungs, not the dreamers who target the hardest rung and fail.
The Localization Ladder: climbing pharma value the achievable way
Here is the framework I use to keep pharma-localization ambition matched to economic reality. Call it the Localization Ladder — four rungs, climbed in order, each viable and policy-supported, with API at the top reached only when scale allows.
Rung 1 — Packaging and supply ecosystem. The lowest-risk entry: cold chain, packaging, lab services, quality assurance, and component supply. Cash-generating, capital-light, and riding the whole sector’s growth. This is where most East African entrepreneurs should start — supplying the industry rather than trying to be it.
Rung 2 — Fill-finish. Formulating and finishing imported or regional active ingredients into final dosage forms. Moderately capital-intensive, directly favored by local-production procurement rules, and the rung the BioNTech-style anchors and policy targets most directly enable. This is the achievable manufacturing entry point.
Rung 3 — Generics manufacturing. Producing off-patent, high-volume medicines for the region’s disease burden. Serves certain, enormous demand, benefits from procurement preferences, and builds genuine pharmaceutical-manufacturing capability and credibility.
Rung 4 — Active pharmaceutical ingredients (later, with scale). The capital-intensive top rung. Approached only when regional demand, capital, and capability have aggregated enough to compete with global API producers — a goal for the next phase, not the entry point. The five API plants on the continent today show how high this rung is (5).
The Localization Ladder turns a daunting industrial ambition into a sequenced, achievable strategy. Start at the bottom — packaging and supply — where the economics work today; climb to fill-finish and generics, where policy guarantees demand; and reach for APIs only when scale earns it. This is how an industry is built: rung by rung, not by leaping for the top and falling.
What should operators, investors, and policymakers do?
The agenda is clear and the timing — a protected runway created by policy — is favorable.
For entrepreneurs, the opportunity is to build the achievable rungs around the anchors and the policy demand: packaging, cold chain, lab services, fill-finish, and generics. These are real manufacturing and industrial-supply businesses with policy-guaranteed demand, and they fit the structured and asset-backed financing the region’s capital base increasingly supports. The sector also connects tightly to healthtech’s pharmacy rails, which provide the last-mile distribution and demand data that local manufacturers need, and to the region’s industrial-policy and SEZ infrastructure.
For investors, pharma localization offers the unusual combination of policy-guaranteed demand, strategic importance, and a protected runway for first movers — exactly the kind of long-horizon industrial opportunity that aligns with patient capital and with the region’s industrial partnerships, including Japan’s manufacturing and supply-chain engagement. For policymakers, the imperative is to make the demand certainty real: honor local-production procurement preferences, support quality certification and skills, and structure the financing that lets the achievable rungs get built. The Africa CDC 60%-by-2040 target only works if the procurement and financing follow it.
The conclusion captures why this sector is special. Most opportunities require betting on demand or fighting for market share. Pharma localization is different: the demand is being deliberately guaranteed by policy, the strategic importance is recognized at the highest levels, and the financing — from the EU, the IFC, China, and CEPI — is actively flowing (1)(3)(4). The Kigali BioNTainer is not a one-off showpiece; it is the anchor tenant of an industry East Africa will need for a century, and proof that the high end can be built here. The discipline required is to match ambition to the achievable rungs — to make the packaging, the fill-finish, the generics here first, and the active ingredients later. Make the medicine here, rung by rung, and East Africa builds not just health security but a durable manufacturing industry on a foundation of guaranteed demand. Few sectors offer an alignment that clean.
FAQ
How much of its medicine does Africa import?
More than 95% of pharmaceuticals consumed in Africa are imported. COVID exposed this dependency as a strategic vulnerability when global supply chains seized and the continent was last in line for vaccines and essential medicines — turning pharma localization into an industrial and health-security priority.
What is the BioNTech facility in Rwanda?
BioNTech’s 35,000 m² mRNA vaccine manufacturing facility in Kigali is the first commercial mRNA plant in Africa. It won up to €95 million in EU blended financing (a €35M EC grant plus a potential €60M EIB loan), with a CEPI grant of up to €130 million, to produce vaccines for malaria, TB, HIV, and mpox (1)(2).
Should East African entrepreneurs try to make active pharmaceutical ingredients?
Generally not yet. API production is extraordinarily capital-intensive and scale-dependent — only about five API plants exist on the entire continent. The realistic near-term opportunity is fill-finish, generics, packaging, and the supplier ecosystem, which are viable today and benefit from local-production procurement preferences (5).
Why is pharma manufacturing a “protected runway” opportunity?
Because demand is being deliberately steered toward local production by policy — Africa CDC targets 60% local vaccine production by 2040, and procurement rules favor local manufacturers. First movers who build quality capability get a market that policy is guaranteeing, rather than having to win it in open competition (5).
What is the most achievable entry point in pharma manufacturing?
The supply ecosystem and fill-finish: packaging, cold chain, lab services, quality assurance, and the formulation/finishing of medicines into final dosage forms. These are lower-risk, cash-generating, and directly favored by procurement policy — the bottom rungs of a value chain that climbs toward generics and, eventually, active ingredients.
Related Reading
- The Pharmacy Is the Hospital: Healthtech’s Quiet Compounding
- Rwanda: The Proof-of-Concept State
- The Gulf Bridge: CEPA and East Africa’s New Trade Geography
- TICAD 9: Japanese Investment and East Africa’s Industrial Strategy
Sources and Evidence
- European Investment Bank — “EIB and European Commission join forces with BioNTech to build a sustainable vaccine ecosystem in Africa” — Primary source for the up-to-€95M blended financing (€35M EC grant + €60M EIB loan) and the CEPI grant up to €130M.
- Pharmaceutical Technology — “BioNTech mRNA Vaccine Manufacturing Facility, Rwanda” — Source for the 35,000 m² facility, its first-in-Africa status, and target diseases (malaria, TB, HIV, mpox).
- NewsCentral — “Africa focuses on local production for pharma growth” — Documents Kenya’s $500 million deal with China for local vaccine and pharmaceutical production.
- IFC — “Answering Africa’s call for private investment in pharma manufacturing” — Source on the IFC actively recruiting private capital into African pharmaceutical manufacturing.
- African Business — “Momentum builds for local drug production” — Source for the ~five API plants on the continent, the >$50 billion African pharma market, and Africa CDC’s 60%-by-2040 target.